Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients

Journal of Immunotherapy

Volumn 35, Issue 5, 2012, Pages 440-447

  Botta, Cirino ^a   Bestoso, Elena ^a   Apollinari, Serena ^a   Cusi, Maria Grazia ^b   Pastina, Pierpaolo ^a   Abbruzzese, Alberto ^c   Sperlongano, Pasquale ^c   Misso, Gabriella ^c   Caraglia, Michele ^c   Tassone, Pierfrancesco ^d   Tagliaferri, Pierosandro ^d   Correale, Pierpaolo ^a  

^a Medical Oncology Unit   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Cetuximab; Colorectal cancer; Epidermal growth factor receptor; Polychemotherapy

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CD14 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD45RA ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CETUXIMAB; CHEMOKINE RECEPTOR CCR7; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITOPE; FC RECEPTOR; FLUOROURACIL; FOLINIC ACID; GAMMA INTERFERON; GEMCITABINE; GLYCOPROTEIN P 15095; HLA A ANTIGEN; IMMUNOGLOBULIN G1; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; IRINOTECAN; L SELECTIN; OXALIPLATIN; RECOMBINANT INTERLEUKIN 2; THYMIDYLATE SYNTHASE; TRANSCRIPTION FACTOR FOXP3;

ADULT; ADVANCED CANCER; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL COMPARTMENTALIZATION; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DENDRITIC CELL; DRUG RECEPTOR BINDING; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPHENOTYPING; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; MALE; MEMORY T LYMPHOCYTE; METRONOMIC DRUG ADMINISTRATION; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHAGOCYTOSIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; T LYMPHOCYTE; TH1 CELL; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CASE-CONTROL STUDIES; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DENDRITIC CELLS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; IMMUNOMODULATION; IMMUNOTHERAPY; INTERLEUKIN-2; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT PROTEINS; T-LYMPHOCYTE SUBSETS;

EID: 84861235490     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31825943aa     Document Type: Article

References (37)

1. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 2004;59:21-26. (Pubitemid 38610223)
2. Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001;37:S3-S8. (Pubitemid 32938123)
3. Mass RD. The HER receptor family: a rich target for therapeutic development. Int J Radiat Oncol Biol Phys. 2004;58:932-940. (Pubitemid 38221153)
4. Mendelsohn J, Fan Z. Epidermal growth factor receptor family and chemosensitization. J Natl Cancer. 1997;89:341-343. (Pubitemid 27102599)
5. Prewett MC, Hooper AT, Bassi R, et al. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumour xenografts. Clin Cancer Res. 2002;8:994-1003. (Pubitemid 34517632)
6. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757-1765.
7. Correale P, Cusi MG, Del Vecchio MT, et al. Dendritic cellmediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro. J Immunol. 2005;175:820-828. (Pubitemid 41094964)
8. Correale P, Marra M, Remondo C, et al. Cytotoxic drugs upregulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFRtargeted antibody-dependent cell-mediated-cytotoxicity (ADCC). Eur J Cancer. 2010;46:1703-1711.
9. Clynes R. Antitumor antibodies in the treatment of cancer: Fc receptors link opsonic antibody with cellular immunity. Hematol Oncol Clin North Am. 2006;20:585-612. (Pubitemid 43817439)
10. Kalergis AM, Ravetch JV. Inducing tumor immunity through the selective engagement of activating Fcg receptors on dendritic cells. J Exp Med. 2002;195:1653-1659. (Pubitemid 34666079)
11. Liu YJ, Kanzler H, Soumelis V, et al. Dendritic cell lineage, plasticity and cross-regulation. Nat Immunol. 2001;2:585-589. (Pubitemid 32677624)
12. Tsang KY, Zaremba S, Nieroda CA, et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst. 1995;87:982-990.
13. Correale P, Del Vecchio MT, Di Genova G, et al. 5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine. J Natl Cancer Inst. 2005;97:1437-1445. (Pubitemid 41520079)
14. Hara M, Nakanishi H, Tsujimura K, et al. Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity. Cancer Sci. 2008;99:1471-1478. (Pubitemid 351761740)
15. Correale P, Campoccia G, Tsang KY, et al. Recruitment of dendritic cells and enhanced antigen-specific immune reactivity in cancer patients treated with hr-GM-CSF (Molgramostim) and hr-IL-2. results from a phase Ib clinical trial. Eur J Cancer. 2001;37:892-902. (Pubitemid 32323968)
16. Roda JM, Joshi T, Butchar JP, et al. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res. 2007;13:6419-6428. (Pubitemid 350075032)
17. Milani V, Stangl S, Issels R, et al. Anti-tumor activity of patient-derived NK cells after cell-based immunotherapy-a case report. J Transl Med. 2009;7:50-68.
18. Carter LL, Swain SL. Single cell analyses of cytokine production. Curr Opin Immunol. 1997;9:177-182. (Pubitemid 27190115)
19. Correale P, Aquino A, Giuliani A, et al. Treatment of colon and breast carcinoma cells with 5-fluoruracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A(*)02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro. Int J Cancer. 2003;104:437-445. (Pubitemid 36323913)
20. Correale P, Sabatino M, Cusi MG, et al. In vitro generation of cytotoxic T lymphocytes against HLA-A2.1-restricted peptides derived from human thymidylate synthase. J Chemother. 2001;13:519-526. (Pubitemid 33001115)
21. Ferrone C, Dranoff G. Dual roles for immunity in gastrointestinal cancers. J Clin Oncol. 2010;28:4045-4051.
22. Correale P, Cusi MG, Tagliaferri P. Immunomodulatory properties of anticancer monoclonal antibodies: is the 'magic bullet' still a reliable paradigm? Immunotherapy. 2011; 3:1-4.
23. Correale P, Botta C, Cusi MG, et al. Cetuximab +-chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro. Int J Cancer. 2011;130:1577-1589.
24. Klinger A, Gebert A, Bieber K, et al. Cyclical expression of L-selectin (CD62L) by recirculating T cells. Int Immunol. 2009;21:443-455.
25. Beauvillain C, Cunin P, Doni A, et al. CCR7 is involved in the migration of neutrophils to lymph nodes. Blood. 2011;117: 1196-1204.
26. Janssen EM, Lemmens EE, Wolfe T, et al. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature. 2003;421:852-856. (Pubitemid 36254145)
27. Romagnani S. Type 1 T helper and type 2 T helper cells: functions, regulation and role in protection and disease. Int J Clin Lab Res. 1991;21:152-158.
28. Correale P, Rotundo MS, Del Vecchio MT, et al. Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J Immunother. 2010;33:435-441.
29. López-Albaitero A, Lee SC, Morgan S, et al. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother. 2009;58:1853-1864.
30. Kang X, Patel D, Ng S, et al. High affinity Fc receptor binding and potent induction of antibody-dependent cellular cytotoxicity (ADCC) in vitro by anti-epidermal growth factor receptor antibody cetuximab. J Clin Oncol. 2007;25:3041. Abstract.
31. Mimura K, Kono K, Hanawa M, et al. Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma. Clin Cancer Res. 2005;11:4898-4904. (Pubitemid 41557210)
32. McDonnell AM, Robinson BW, Currie AJ. Tumor antigen cross-presentation and the dendritic cell: where it all begins? Clin Dev Immunol. 2010;2010:539519. Abstract.
33. Beum PV, Mack DA, Pawluczkowycz AW, et al. Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes. J Immunol. 2008;181:8120-8132.
34. Roda JM, Parihar R, Magro C, et al. Natural killer cells produce T cell-recruiting chemokines in response to antibodycoated tumor cells. Cancer Res. 2006;66:517-526. (Pubitemid 43166061)
35. Kalinski P, Mailliard RB, Giermasz A, et al. Natural killerdendritic cell cross-talk in cancer immunotherapy. Expert Opin Biol Ther. 2005;5:1303-1315. (Pubitemid 41503042)
36. Shaw DR, Griffin FM. Phagocytosis requires repeated triggering of macrophage phagocytic receptors during particle ingestion. Nature. 1981;289:409-411. (Pubitemid 11135151)
37. Bibeau F, Lopez-Crapez E, Di Fiore F, et al. Impact of FcgRIIa-FcgRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol. 2009;27:1122-1129.